Naarden, P7CIK 20134104 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
10 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Newamsterdam Pharma Company | 9.20M | $322.70M | 42.3% | −13.5K | Reduced |
| 2 | Dyne Therapeutics Inc | 5.46M | $106.85M | 14.0% | 0 | Held |
| 3 | Engene Holdings Inc | 9.63M | $86.98M | 11.4% | 0 | Held |
| 4 |
| 1.83M |
| $62.09M |
| 8.1% |
| +1.49M |
| Added |
| 5 | Maplight Therapeutics Inc | 3.23M | $56.67M | 7.4% | +3.23M | New |
| 6 | Vor Biopharma Inc | 3.62M | $47.31M | 6.2% | +3.24M | Added |
| 7 | Replimune Group Inc | 2.81M | $27.30M | 3.6% | −1.35M | Reduced |
| 8 | Bicycle Therapeutics PLC | 3.47M | $24.56M | 3.2% | +16.1K | Added |
| 9 | Crescent Biopharma Inc. | 1.68M | $19.90M | 2.6% | +1.68M | New |
| 10 | Engene Holdings Inc | 2.88M | $8.52M | 1.1% | 0 | Held |